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istoric advances in biomedical 
research provide both 
unprecedented insights into 
the pathogenesis of human diseases 
and the challenge to translate these 
insights efﬁ  ciently into improved 
health. Meeting this challenge requires 
the creation of a robust translational 
and clinical research enterprise [1], 
which, in turn, depends critically 
on the ability of academic medicine 
to produce and support enough 
physician–scientists to enable the 
enterprise. 
    Yet, academic translational and 
clinical research in the United States 
continues to face serious obstacles. 
These obstacles include the sharply 
diminishing ability of clinical 
departments to underwrite research 
from patient-care revenues; a declining 
share of industry-sponsored clinical 
trials; the prospect of ﬂ  at or declining 
National Institutes of Health (NIH) 
budgets over the near term; the 
perceived disadvantage of clinical 
research applications in NIH peer 
review; overly burdensome regulatory 
requirements; undervaluation by 
academic medical culture; and the lure 
of greater ﬁ  nancial rewards, and even 
professional satisfaction, in full-time 
clinical practice. 
    Responding to this challenge, the 
Association of American Medical 
Colleges convened its second Clinical 
Research Task Force (CRTF II) 
to advise the academic medical 
community how best to (1) attract, 
develop, and nurture increased 
numbers of independent translational 
and clinical investigators; (2) create 
infrastructure needed for these 
investigators to be successful; and 
(3) ﬁ  nance translational and clinical 
science. 
    This Policy Forum summarizes the 
task force’s recommendations and 
conclusions, which are animated by the 
vision of an academic medical culture 
that values and supports translational 
and clinical research; transmits the 
excitement of such research to medical 
students, residents, and postdoctoral 
fellows; and establishes viable and 
appealing career paths for physician 
investigators who conduct such 
research. The full report, which is 
available both in monograph and on 
the Web [2], focuses speciﬁ  cally on the 
obstacles facing academic translational 
and clinical research in the US; a 
recent report addresses related issues in 
the United Kingdom [3].
  Developing  and  Nurturing 
Translational and Clinical 
Physician–Scientists
      Education.   Every future physician 
should receive a thorough education 
in the basic principles of translational 
and clinical research, both in medical 
school and during residency training. 
The Liaison Committee on Medical 
Education (the accrediting body for all 
US allopathic medical schools) should 
add education in translational and 
clinical research to the requirements 
for medical school accreditation, and 
the Accreditation Council for Graduate 
Medical Education (the accrediting 
body for specialty training programs) 
should embed the understanding of 
translational and clinical research 
within its required core competencies. 
By choosing these recommendations 
to open its report, the task force 
underscores the importance of 
requiring all future physicians to 
be educated in the principles and 
methodologies of translational and 
clinical research. This would send 
a clear signal that the institution’s 
leadership and faculty consider such 
research part of the core mission of 
academic medicine, and understanding 
it, a foundational element of medical 
education. The requirement would, 
at minimum, better equip physicians 
to (1) read the medical literature 
and evaluate the signiﬁ  cance and 
implications of published discoveries 
and new treatments in their own 
disciplines, which is essential for the 
realization of evidence-based medicine; 
(2) communicate knowledgeably 
with clinical researchers; (3) explain 
translational and clinical research 
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in a way that is comprehensible to 
their patients and refer them, when 
appropriate, for screening for clinical 
trials; and (4) be powerful advocates for 
translational and clinical research with 
the public. These are all appropriate 
objectives for medical school graduates 
irrespective of their career choices. 
    Equally important, early exposure of 
medical students to translational and 
clinical research will enhance their 
awareness of it and stimulate some to 
consider making it their career. To 
put teeth into Recommendation 1, 
CRTF II urges the two US accrediting 
organizations that oversee the formal 
phases of medical education to 
incorporate meaningful exposure to 
translational and clinical research into 
their accreditation standards. 
      Training.   Training for translational 
and clinical investigators should 
comprise the completion of an 
advanced degree with a thesis 
project (or equivalent educational 
experience), appropriate mentoring, 
and a substantive postdoctoral training 
experience. Translational and clinical 
research has grown sufﬁ  ciently 
complex that training should include 
a degree program (at minimum, 
Master’s level) with a core curriculum 
and mentored thesis project, as well 
as an additional two to three years 
of rigorous, mentored postdoctoral 
experience to prepare trainees for 
independence. Providing trainees with 
opportunities to develop a record of 
accomplishment will enhance their 
attractiveness as candidates for junior 
faculty appointments. A foundational 
element of this recommendation is 
the need for institutional support of 
mentors, who are essential for success. 
      Support.   Sufﬁ  cient support should 
be given to new junior faculty who are 
translational and clinical investigators 
to maximize their probability of 
success. New junior faculty in 
translational and clinical science 
require start-up support comparable 
to that which is provided in basic 
science—i.e., sufﬁ  cient to establish an 
independent research program. This 
support includes space for research, 
salary support to protect ample time for 
research (often 75%), and resources to 
access the necessary infrastructure—
e.g., biostatistics, study coordinators, 
laboratory and imaging cores, and 
informatics. Because of the complex 
nature and regulatory requirements 
of translational and clinical research, 
junior faculty continue to need 
effective, individually focused 
mentoring, and this should be overseen 
by the institution. Institutional policy 
must also be ﬂ  exible enough to address 
the special needs of faculty who wish to 
start families. 
      Accelerated training.   Training in 
translational and clinical research 
should be accelerated through 
comprehensive re-structuring to enable 
trainees to become independent 
clinicians and investigators at the 
earliest possible time. The average 
age to receive one’s ﬁ  rst R01 grant 
(investigator-initiated research 
project grant) from the NIH has been 
steadily increasing, and is now 42 
years old for a PhD and 43 years old 
for an MD. The CRTF II is especially 
troubled by the effect that this delay 
in achieving independent funding 
has on recruitment into translational 
and clinical research. A number of 
US institutions have incorporated 
elements of translational and clinical 
research training—including Master’s 
degree programs—into medical school, 
residencies, or fellowships without 
adding signiﬁ  cantly to the total amount 
of time in training. However, the task 
force envisions more fundamental 
restructuring that would begin early in 
medical school and continue seamlessly 
through residency and fellowship 
training to prepare graduates to 
compete for independent research 
funding at an earlier age. This would 
permit graduates to begin contributing 
to science during their years of highest 
creativity, and have more productive 
years in their careers. The Association 
of American Medical Colleges intends 
to facilitate such a reengineering effort.
      Academic recognition.   Institutions, 
journals, the NIH, and other research 
sponsors should take steps to facilitate 
appropriate academic recognition of 
translational and clinical scientists for 
their contributions to collaborative 
research. Career advancement of 
academic translational and clinical 
scientists requires that they be given 
appropriate credit for their roles 
in conceptualizing, implementing, 
and obtaining research funding 
for published research. This 
becomes especially important as 
biomedical research becomes more 
multidisciplinary and team oriented. 
All journals should require (as some 
already do) a description of each 
author’s contribution to submitted 
manuscripts, and this information 
should be published with the article or 
should be accessible online. The NIH 
should modify its Computer Retrieval 
of Information on Scientiﬁ  c Projects 
(the NIH’s comprehensive online 
database of all NIH-funded grants) to 
list, in a searchable fashion, the roles 
of all co-investigators in funded grants 
and contracts.
      K23 and K24 awards.   The NIH 
should modify the K23 and K24 awards 
to enhance their value in supporting 
clinical and translational research 
training and mentoring. K23 grants 
are mentored patient-oriented career 
development awards that provide 
partial salary support for clinical 
physician research trainees. K24 
grants are mid-career patient-oriented 
research awards that provide salary 
support for 50% effort by clinical 
physician investigators for mentoring 
and conducting clinical research. CRTF 
II believes that all translational and 
clinical research trainees supported by 
NIH K23 grants should be supported 
for their stipulated effort at salary rates 
up to the legislative cap (US$183,500 
in 2006), and that the awards should 
provide substantial support for the 
trainees’ own projects. Acknowledging 
the NIH’s presently constrained 
budget, CRTF II believes that fewer 
awards modiﬁ  ed as recommended 
would better serve the goal of 
preparing trainees for independent 
careers. 
    The NIH should modify the K24 
grants to allow any investigators who 
are independently funded by the 
NIH for patient-oriented research to 
apply, by permitting ﬂ  exibility in the 
acceptable level of effort for mentoring 
(10%–50%). This would permit many 
more patient-oriented investigators 
to become eligible and likely take 
advantage of this support. 
  Administration  and  Infrastructure 
for Translational and Clinical 
Science
      Oversight, administration, and 
support.   Institutions should provide 
central oversight, administration, and 
support for the essential infrastructure 
required by the translational 
and clinical research enterprise. 
Centralized institutional leadership 
can powerfully enable translational 
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and clinical research by promoting 
a culture in which translational 
and clinical research is vibrant and 
visible, strengthening the identity and 
morale of translational and clinical 
scientists, enabling strategic planning 
and targeted investment of resources, 
and promoting cohesion among the 
various components and partnerships 
across medical school departments and 
other schools. Centralized oversight 
and support of core resources will 
enhance usage by providing fair, 
unimpeded access for any faculty 
member who needs their services, 
as well as operational advantages. 
Such advantages include efﬁ  ciency, 
cost savings, continuity of funding, 
availability of backup personnel, 
uniform operating procedures and 
training that improve compliance, and 
uniform standards for the qualiﬁ  cations 
and experience of support personnel. 
      Human research protection 
programs.   Human research protection 
programs (institutional programs that 
provide program support including 
training, administration, and quality 
control for the human research 
protections functions including the 
institutional review boards [IRBs; 
research ethics committees]) should 
be made more effective and efﬁ  cient 
by (1) transagency harmonization of 
federal regulations, (2) accreditation of 
human research protection programs, 
(3) simpliﬁ  cation of institutional 
regulatory compliance processes, 
and (4) expanded use of central 
IRBs (research ethics committees) 
in multisite research. US regulations 
pertinent to translational and clinical 
research and compliance should be 
simpliﬁ  ed and harmonized between 
the NIH and the Food and Drug 
Administration. Institutions should 
seek accreditation for their human 
research protection programs: this 
will help establish an institutional 
“culture of responsibility,” lead to 
adoption of operating procedures 
that meet a national standard and are 
consistent across the academic medical 
community, and provide uniform 
education for faculty, trainees, and staff. 
    To minimize regulatory burdens 
on faculty, institutions should strive 
to create process improvements, 
e.g., a common renewal date for all 
compliance approvals required for each 
research study. To expedite approval 
of protocols and mitigate the burdens 
on individual IRBs and faculty time, 
as well as faculty frustration, academic 
institutions should make greater 
use of commercial, governmentally 
established, or institutionally 
designated central IRBs, especially 
for multisite trials. Wide adoption of 
human research protection program 
accreditation could help to promote 
this change. 
      National forum.   A national forum 
should be established to (1) facilitate 
development of clinical information 
systems that integrate data from diverse 
clinical and research information 
platforms, and to (2) develop DNA and 
tissue banks that correlate genotypic 
and phenotypic data and ensure 
regulatory compliance. Enabling 
translational and clinical research to 
reach its full potential, while keeping 
costs manageable, will require (1) 
the development of costly new 
generations of clinical information 
systems that can link clinical research 
databases across different platforms, 
and (2) the establishment of DNA 
and human tissue banks that adhere 
to common, rigorous operating 
standards, that are compliant with 
regulatory requirements, and that 
can enable correlation of genotypic 
and phenotypic information. These 
objectives could be accomplished most 
rapidly with minimum duplication by 
establishing a national forum in which 
government, industry, and institutions 
can share knowledge, information, 
and resources. One potential goal 
for a national forum would be to 
enumerate the unique information 
needs of clinical research databases 
that distinguish them from existing 
electronic medical records.
      Collaborations.   Academic 
medical institutions should establish 
collaborations with community health-
care providers and practice-based 
research networks to broaden the 
diversity and size of the population 
base for translational and clinical 
research and to increase opportunities 
for health services, epidemiological, 
and outcomes research. The US 
is rapidly becoming a nation of 
“minorities”; in the relatively near 
future, no ethnic or racial group 
in the country will exceed 50% of 
the population. Medical research 
will fail to reach its full promise and 
potential if it is not conducted by 
an appropriately diverse workforce 
in representative populations. The 
recruitment of sufﬁ  cient numbers 
of appropriate research participants 
will be impossible without developing 
genuine partnerships with communities 
and local health-care providers. More 
effective linkages among academic 
medical centers, their Veterans 
Administration Medical Center 
afﬁ  liates, community physicians, 
and practice-based networks will 
require institutions to invest in 
infrastructure, as well as in training 
for faculty, staff, and students in 
the principles and challenges of 
community-based research. Forming 
collaborative relationships will require 
institutions to demonstrate their 
ability to accommodate the interests 
of communities and their physicians, 
as well as those of faculty, such that all 
participants perceive beneﬁ  t.
  Financing  for  Translational 
and Clinical Science
    Medical schools and their afﬁ  liated 
teaching hospitals should explicitly 
recognize and vigorously promote 
translational and clinical research as 
a core mission, and grant it a high 
priority for institutional funding. 
Leaders of institutions that have had 
success in developing translational 
and clinical science highly value this 
ﬁ  eld of science, and visibly foster a 
supportive institutional culture. The 
leadership of every medical school 
has discretionary funds to invest in its 
missions, and institutions that value 
translational and clinical research make 
it a high priority for funding. Support 
is provided for trainees, junior faculty, 
and core infrastructure to create 
viable and appealing career paths for 
translational and clinical investigators. 
Successful institutions do not need 
large endowments or resources—
impressive translational and clinical 
research programs can be built by 
targeting investments in focused areas, 
leveraging available resources through 
sponsored programs, and maximizing 
collaborations.
  Conclusion
    Academic medicine has played a 
central role in partnering with the 
NIH and Industry to make the 21st 
century the “Century of Biology.” Now, 
academic medicine must also vigorously 
assert its leadership in translating that 
biology into better health for all.   
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